Hepatitis C Patients with Cirrhosis in Primary Care Clinics: Implementing Evidence-Based. Guidelines

Similar documents
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Causes of Liver Disease in US

Variceal bleeding. Mainz,

Learning Objectives. After attending this presentation, participants will be able to:

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?

ESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015

End-Stage Liver Disease (ESLD): A Guide for HIV Physicians

Validation of Clinical Outcomes in Electronic Data Sources

Michele Bettinelli RN CCRN Lahey Health and Medical Center

Evidence-Base Management of Esophageal and Gastric Varices

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Care of the Patient With Cirrhosis

Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation

Carvedilol or Propranolol in the Management of Portal Hypertension?

CIRRHOSIS Definition

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Index. Note: Page numbers of article titles are in boldface type.

Hepatitis and pregnancy

Module 1 Introduction of hepatitis

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension

Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate

Conflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.

Chronic liver disease generally

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice

Life After SVR for Cirrhotic HCV

COMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY

Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1

Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding Raines D L, Dupont A W, Arguedas M R

Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis?

GI bleeding in chronic liver disease

Case Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France

Cirrhosis the end stage of chronic liver disease characterized

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

ISR Process for Internal Service Providers

Ontario s Adult Referral and Listing Criteria for Liver Transplantation

Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:

ENCORE-PH Top-line Results

The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

REVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.

Cost-effectiveness analysis of beta-blockers vs endoscopic surveillance in patients with cirrhosis and small varices

Hepatocellular Carcinoma: Diagnosis and Management

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Outreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial

Beta-blockers in cirrhosis: Cons

Paul Martin MD FACG. University of Miami

Hepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM

HCV care after cure. This program is supported by educational grants from

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018

Detection of Esophageal Varices Using CT and MRI

Medical Necessity Guidelines: Upper GI Endoscopy: Certain Elective Procedures

th Annual AISF Meeting 44 th th th, 2011 Rome, February 23 rd -26

Meet the Professor: HIV/HCV Coinfection

Hepatitis C Policy Discussion

Hepatology For The Nonhepatologist

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice

NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

Stick or twist management options in hepatitis C

Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice

2.0 Synopsis. Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, RBV M Clinical Study Report R&D/16/1328. (For National Authority Use Only)

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

ENDOSCOPIC LIGATION OF ESOPHAGEAL VARICES LONG TERM RESULTS

Liver disease in 2017: challenges and opportunities

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Clinical Trials & Endpoints in NASH Cirrhosis

A. Purpose and Scope of the Guidance PRACTICE GUIDANCE HEPATOLOGY, VOL. 65, NO. 1, 2017

ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT

Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis

Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy

PROGRAMME AT A GLANCE

DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL

Hepatocellular Carcinoma: Epidemiology and Screening

HCC Screening Compliance Module: A Tool for Automated Compliance Monitoring, Clinician Notification, and Efficacy Research

HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME

Hepatitis C Virus (HCV)

Surveillance for Hepatocellular Carcinoma

Index. Note: Page numbers of article titles are in boldface type.

MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Sandipan Ghose, Md. Azizul Hoque, Md. Khalilur Rahman, Mohd. Harun-or-Rashid

CURRICULUM VITAE. Iliana Simeonova Bouneva, MD

Management of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy

Is exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population

Evaluation and Prognosis of Patients with Cirrhosis

Hepatocellular Carcinoma Surveillance

Hepatology for the Nonhepatologist

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

Screening for hepatocellular carcinoma (HCC) is controversial.

Natural history of α-1-atd in children

Worldwide Causes of HCC

BETA-BLOCKERS IN CIRRHOSIS.PRO.

Transcription:

Hepatitis C Patients with Cirrhosis in Primary Care Clinics: Implementing Evidence-Based Guidelines Poster Presentation Handout for Scholarly Event March 26, 2013 Michelle M. Lisowski NURS 770: Clinical Scholarship IV Winona State University

Educational Items Distributed to Primary Care Providers 1. Clinicians Guide The full text or pdf of this document can be found and downloaded at www.hepatitis.va.gov. This document is not copyrighted and users are encouraged to print and distribute as many copies as they need.

2. Laminated Pocket Card Cirrhosis Treatment Recommendations HCC surveillance (every 6 months): Ultrasound AFP No varices Part of the Cirrhosis Quicknotes which constitute an abbreviated version of the Management and Treatment of Patients with Cirrhosis and Portal Hypertension (2009), developed by the Department of Veterans Affairs Hepatitis C Resource Center Program. Repeat endoscopy in 3 years (sooner if decompensation occurs) Management of compensated cirrhosis (no ascites, variceal hemorrhage, encephalopathy, or jaundice) Varices surveillance (upper endoscopy) Small varices In a CTP class B or C patient or varices with red signs In a CTP class A patient, without red signs Nonselective betablockers (propranolol or nadolol) Nonselective beta-blockers optional Start propranolol (20 mg BID) or nadolol (40 mg QD) Titrate to maximum tolerable dosage or a heart rate of 55-60 beats/min No need to repeat endoscopy If no beta-blockers given, repeat endoscopy in 2 years (sooner if decompensation occurs) Medium/Large varices prevention of first variceal hemorrhage Nonselective beta-blockers (propranolol, nadolol) OR Endoscopic variceal ligation (choice depends on patient characteristics and preferences, local resources) Start propranolol (20 mg BID) or nadolol (40 mg QD) Titrate to maximum tolerable dosage or a heart rate of 55-60 beats/min No need to repeat endoscopy Ligate every 1-2 weeks until variceal obliteration First surveillance endoscopy 1-3 months after obliteration, then every 6-12 months indefinitely

3. Hepatocellular Carcinoma Pocket Card from GuidelineCentral.com (Pocket card is copyrighted not able to past to this document) Article on diagnosing cirrhosis sent to providers 1-2 weeks post educational seminar: Udell, J. A., Wang, C. S., Tinmouth, J., FitzGerald, J. M., Ayas, N. T., Simel, D. L.,... Yoshida, E. M. (2012). Does this patient with liver disease have cirrhosis? The Journal of the American Medical Association, 307(8), 832-842.

References Ackley, B. J., Swan, B. A., Ladwig, G., & Tucker, S. (2008). Evidence-based nursing care guidelines: Medical-surgical interventions. St. Louis, Missouri: Mosby Elsevier. Bacon, B. R., O'Grady, J. G., Di Bisceglie, A. M., & Lake, J. R. (2006). Comprehensive clinical hepatology. Philadelpha, Pennsylvania: Mosby. Bruix, J., & Sherman, M. (2005). Management of hepatocellular carcinoma. Hepatology, 42(5), 1208-1236. Bruix, J., & Sherman, M. (2011). management of hepatocellular carcinoma: An update. Hepatology, 53(3), 1020-1022. doi:10.1002/hep.24199 Center for Quality Management in Public Health. (2010). The state of care for Veterans with chronic hepatitis C. Palo Alto: U.S. Department of Veteran Affairs, Publich Health Strategic Health Care Group, Center for Quality Management in Public Health. Retrieved from http://www.hepatitis.va.gov/pdf/hcv-state-of-care-2010.pdf Chou, A. F., Vaughn, T. E., McCoy, K. D., & Doebbeling, B. N. (2011). Implementation of evidence-based practices: Applying a goal commitment framework. Health Care Management Review, 36(1), 4-17. doi:10.1097/hmr.0b013e3181dc8233 Cohen, S. M., & Kataoka-Yahiro, M. (2010). Provider adherence to clinical guidelines related to lipid-lowering medications. Military Medicine, 175, 122-126. Craig, T. J., Perlin, J. B., & Fleming, B. B. (2007). Self-reported performance improvement strategies of highly successful Veterans Health Administration facilities. American Journal of Medical Quality, 22, 438-444. doi:10.1177/1062860607304928 Demakis, J. G., Beauchamp, C., Cull, W. L., Denwood, R., Eisen, S. A., Lofgren, R.,... Henderson, W. G. (2000). Improving residents' compliance with standards of ambulatory care: Results from the VA cooperative study on computerized reminders. Journal of the American Medical Association, 284(11), 1411-1416. Flanagan, M. E., Ramanujam, R., & Doebbeling, B. N. (2009). The effect of provider and workflow focused strategies for guideline implementation on provider acceptance. Implementation Science, 4(71), 1. doi:10.1186/1748-5908-4-71 Garcia-Tsao, G., Sanyal, A. J., Grace, N. D., & Carey, W. (2007). Prevention and management of gastoesophageal varices and variceal hemorrhage in cirrhosis. Hepatology, 922-938. Goetz, M. B., Hoang, T., Bowman, C., Knapp, H., Rossman, B., Smith, R.,... Asch, S. M. (2008). A system-wide intervention to improve HIV testing in the Veterans Health

Administration. Journal of General Internal Medicine, 23(8), 1200-1207. doi:10.1007/s11606-008-0637-6 Grol, R., Wensing, M., Hulscher, M., & Eccles, M. (2005). Theories on implemtation of change in healthcare. In R. Grol, M. Wensing, & M. Eccles, Improving patient care: The implementation of change in clinical practice (pp. 15-40). Edinburgh: Elsevier Butterworth Heinemann. Hysong, S. J., Best, R. G., & Pugh, J. A. (2007). Clinical practice guideline implementatin strategy patterns in Veteran Affairs primary care clinics. Health Research and Educational Trust, 42(1), 84-103. doi:10.1111/j.1475-6773.2006.00610.x Nouso, K., Tanaka, H., Uematsu, S., Shiraga, K., Okamoto, R., Onishi, H.,... Shiratori, Y. (2008). Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. Hepatology, 23, 437-444. doi:10.1111/j.1440-1746.2007.05054.x O'Connor, S., Ward, J. W., Watson, M., Momin, B., & Richardson, L. C. (2010). Hepatocellular Carcinoma---United States, 2001--2006. Centers for Disease Contorl and Prevention. Washington, DC: U.S. Government Printing Office. Richardson, W. S., Wilson, M. C., Nishikawa, J., & Hayward, R. S. (1995). The well-built clinical question: A key to evidence-based decision. ACP Journal Club, 123(3), A12- A13. Saleem, J. J., Patterson, E. S., Militello, L., Render, M. L., Orshansky, G., & Asch, S. (2005). Exploring barriers and facilitators to the use of computerized clinical reminders. Journal of the American Medical Informatics Association, 12(4), 438-447. doi:10.1197/jamia.m1777. Schlosser, R. W., Koul, R., & Costello, J. (2007). Asking well-built questions for evidence-based practice in augmentative and alternative communication. Journal of Communication Disorders, 40, 225-238. doi:10.1016/j.jcomdis.2006.06.008 Spiegel, B. M., Esrailian, E., & Eisen, G. (2007). The budget impact of endoscopic screening for esophageal varices in cirrhosis. Gastrointestinal Endoscopy, 66(4), 679-692. doi:10.1016./j.gie.2007.02.048 Stetler, C. B., Mittman, B. S., & Francis, J. (2008). Overview of the VA Quality Enhancement Research Initiative (QUERI) and QUERI theme articles: QUERI series. Implementation Science, 3(8), 1-13. doi:10.1186/1748-5908-3-8 Stravitz, R. T., Heuman, D. M., Chand, N., Sterling, R. K., Shiffman, M. L., Luketic, V. A.,... Fisher, R. A. (2008). Surveillance for hepatocellular carcinoma in patients with cirrhosis

improves outcome. The American Journal of Medicine, 21, 119-126. doi:10.1016/j.amjmed.2007.09.020 Udell, J. A., Wang, C. S., Tinmouth, J., FitzGerald, J. M., Ayas, N. T., Simel, D. L.,... Yoshida, E. M. (2012). Does this patient with liver disease have cirrhosis? The Journal of the American Medical Association, 307(8), 832-842. Xu, J., Kochanek, K. D., Murphy, S. L., & Tejada-Vera, B. (2010). Deaths: Final data for 2007. National Vital Statistics Reports, 58(19), 1-73.